UI Hospitals and Clinics
A Phase 3 Study to Evaluate the Efficacy and Safety of Dinaciclib or Ofatumumab in Subjects with Refractory Chronic Lymphocytic Leukemia
The purpose of this study is to test the safety of the research study drug, dinaciclib (MK-7965) and to compare the effectiveness of dinaciclib and ofatumumab in treating patients with Chronic Lymphocytic Leukemia (CLL). This is a research study to test a drug that has not yet been approved for sale. Ofatumumab may be available by prescription for the treatment of CLL. The use of ofatumumab for 12 months has not yet been approved.
Karen Parrott, 319-353-6347
We welcome your feedback! Please help us improve your experience on our website by completing a brief survey.